DOREEN FUKUSHIMA: Open Payments
NPI 1205030111 · CLOVIS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,977 in 129 payments from 12 companies in 2025. Trend: 2023 $4,204 · 2024 $3,958 · 2025 $3,977
Food & beverage: $3,977
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $647 |
| ABBVIE INC. | 20 | $622 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $515 |
| Vanda Pharmaceuticals Inc. | 11 | $378 |
| Neurocrine BioSciences, Inc. | 4 | $365 |
| Axsome Therapeutics, Inc. | 10 | $346 |
| Alkermes, Inc. | 21 | $333 |
| Lundbeck LLC | 11 | $279 |
| E.R. Squibb & Sons, L.L.C. | 5 | $229 |
| Neuronetics, Inc. | 2 | $111 |
Products named: REXULTI, CAPLYTA, VRAYLAR, ABILIFY MAINTENA, FANAPT, INGREZZA, Auvelity, ARISTADA.
Industry payments across CA — which companies pay providers there.
